Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin in Essential Hypertension (Integrated 603A/603B)
NCT03514641Phase 3Completed
- Sponsor
- Theracos, Inc.
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bexagliflozin in essential hypertension (4 arms), sponsored by Theracos, Inc. Primary endpoints: Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12 and Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36. Started Oct 2017; status: completed.
02
Drugs
bexagliflozin
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03514641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514641.